POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinical safety rating: safe
No significant drug interactions Can cause hypernatremia and fluid overload.
Potassium is the primary intracellular cation, essential for nerve impulse transmission, muscle contraction, and acid-base balance. Replacement therapy with potassium chloride corrects hypokalemia by increasing extracellular potassium concentration, restoring normal membrane potential and cellular function.
| Metabolism | Not metabolized; excreted primarily by the kidneys via tubular secretion and passive diffusion. |
| Excretion | Renal: >90% of potassium chloride is excreted unchanged in urine via glomerular filtration and tubular secretion. Fecal/biliary elimination is negligible (<2%) under normal renal function. |
| Half-life | Terminal half-life: 2-4 hours in patients with normal renal function. In renal impairment, half-life may be prolonged up to 12-24 hours, increasing risk of hyperkalemia. |
| Protein binding | Potassium is not protein-bound; exists as free ion. Serum protein binding: <2% (negligible). |
| Volume of Distribution | Apparent Vd: 0.2-0.3 L/kg (total body water). Potassium is primarily intracellular (98%), with only 2% in extracellular fluid. Vd increases in hypokalemia and decreases in hyperkalemia. |
| Bioavailability | Oral: 90-100% (well absorbed from gastrointestinal tract). Intravenous: 100% (complete bioavailability by design). |
| Onset of Action | Intravenous: Immediate (seconds to minutes) based on infusion rate; clinical effect (serum potassium elevation) occurs within 30-60 minutes of starting infusion. Oral: 1-2 hours after ingestion. |
| Duration of Action | Intravenous: 4-6 hours depending on dose and renal function; continuous infusion maintains steady state. Oral: 6-8 hours for sustained-release formulations. |
Intravenous infusion; rate not to exceed 10 mEq/hour (10 mmol/hour) or 0.02 mEq/kg/min (0.02 mmol/kg/min) for adults; maximum concentration 40 mEq/L (40 mmol/L) via peripheral vein; typical dose 20-40 mEq (20-40 mmol) per day.
| Dosage form | INJECTABLE |
| Renal impairment | GFR > 50 mL/min: no adjustment. GFR 10-50 mL/min: reduce dose by 25-50% and monitor serum potassium. GFR < 10 mL/min: avoid or use with extreme caution; maximum dose 20 mEq/day with close monitoring. |
| Liver impairment | No specific adjustment required; however, monitor serum potassium in patients with severe hepatic impairment due to risk of hyperkalemia. |
| Pediatric use | Intravenous infusion; dose 0.5-1 mEq/kg (0.5-1 mmol/kg) per dose, maximum 1 mEq/kg/hour (1 mmol/kg/hour); maximum concentration 40 mEq/L (40 mmol/L) via peripheral vein. |
| Geriatric use | Use with caution; consider reduced baseline renal function; initial dose at lower end of adult range; monitor serum potassium and renal function closely; maximum infusion rate 5 mEq/hour (5 mmol/hour) in elderly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Breastfeeding | Potassium is a normal component of breast milk. Potassium chloride at typical IV or oral replacement doses is considered compatible with breastfeeding. The milk-to-plasma (M/P) ratio for potassium is approximately 1.0. No adverse effects on infant reported. |
| Teratogenic Risk | Potassium chloride at physiologic concentrations is not teratogenic. No evidence of fetal harm at standard replacement doses. However, hyperkalemia or hypokalemia may adversely affect fetal development. First trimester: No known teratogenic risk. Second trimester: No known teratogenic risk. Third trimester: No known teratogenic risk; but maternal electrolyte imbalance can affect fetal cardiac function. |
■ FDA Black Box Warning
Concentrated potassium solutions must be diluted before administration; rapid infusion can cause fatal hyperkalemia and cardiac arrest.
| Common Effects | fluid replacement |
| Serious Effects |
Hyperkalemia; severe renal impairment with oliguria or anuria; conditions causing potassium retention (e.g., systemic acidosis, Addison's disease, severe burns); untreated hypoadrenalism; concurrent potassium-sparing diuretics.
| Precautions | Monitor serum potassium levels and ECG during administration; use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia; avoid rapid infusion; ensure adequate urinary output. |
Loading safety data…
| Fetal Monitoring | Monitor serum potassium levels, renal function, and ECG during infusion. In pregnancy, additional monitoring of maternal fluid balance, urine output, and fetal heart rate if maternal hyperkalemia or hypokalemia develops. |
| Fertility Effects | No known direct effect on fertility. However, severe electrolyte disturbances may impair reproductive function. |